Ifebemtinib and paclitaxel synergistically inhibit the proliferation and metastasis of TNBC by blocking PI3K/Akt pathway through LSD1/PIK3IP1 axis
8.0
来源：
Nature
关键字：
ML brain science
发布时间：
2025-11-28 23:36
摘要：
This research investigates the synergistic effects of Ifebemtinib, a FAK inhibitor, and paclitaxel on triple-negative breast cancer (TNBC). The combination significantly inhibits TNBC cell proliferation and metastasis by blocking the PI3K/Akt pathway through the LSD1/PIK3IP1 axis. The findings suggest a promising therapeutic strategy for TNBC, which is known for its aggressive nature and poor prognosis. The study emphasizes the potential of this combination therapy to enhance treatment outcomes for patients with TNBC.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
1.0
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.5
关键证据
Ifebemtinib and paclitaxel synergistically inhibited TNBC cell proliferation and metastasis.
Combination therapy blocked the PI3K/Akt pathway through the LSD1/PIK3IP1 axis.
The study provides a new therapeutic strategy for TNBC, a challenging cancer type.
真实性检查
否
AI评分总结
This research investigates the synergistic effects of Ifebemtinib, a FAK inhibitor, and paclitaxel on triple-negative breast cancer (TNBC). The combination significantly inhibits TNBC cell proliferation and metastasis by blocking the PI3K/Akt pathway through the LSD1/PIK3IP1 axis. The findings suggest a promising therapeutic strategy for TNBC, which is known for its aggressive nature and poor prognosis. The study emphasizes the potential of this combination therapy to enhance treatment outcomes for patients with TNBC.